Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

Fleischmann, Roy ; van Vollenhoven, Ronald F. ; Smolen, Josef ; Emery, Paul ; Florentinus, Stefan ; Rathmann, Suchitrita ; Kupper, Hartmut ; Kavanaugh, Arthur ; Taylor, Peter ; Genovese, Mark ; Keystone, Edward C. ; Drescher, Edit ; Berclaz, Pierre-Yves ; Lee, Chin ; Fidelus-Gort, Rosalind ; Schlichting, Douglas ; Beattie, Scott ; Luchi, Monica ; Macias, William ; Kavanaugh, Arthur ; Emery, Paul ; van Vollenhoven, Ronald F. ; Dikranian, Ara H. ; Alten, Rieke ; Klearman, Micki ; Musselman, David ; Agarwal, Sunil ; Green, Jennifer ; Gabay, Cem ; Weinblatt, Michael E. ; Schiff, Michael H. ; Fleischmann, Roy ; Valente, Robert ; van der Heijde, Desiree ; Citera, Gustavo ; Zhao, Cathy ; Maldonado, Michael A. ; Rakieh, Chadi ; Nam, Jacqueline L. ; Hunt, Laura ; Villeneuve, Edith ; Bissell, Lesley-Anne ; Das, Sudipto ; Conaghan, Philip ; McGonagle, Dennis ; Wakefield, Richard J. ; Emery, Paul ; Wright, Helen L. ; Thomas, Huw B. ; Moots, Robert ; Edwards, Steven W. ; Hamann, Philip ; Heward, James ; McHugh, Neil ; Lindsay, Mark A. ; Haroon, Muhammad ; Giles, Jon T. ; Winchester, Robert ; FitzGerald, Oliver ; Karaderi, Tugce ; Cohen, Carla J. ; Keidel, Sarah ; Appleton, Louise H. ; Macfarlane, Gary J. ; Siebert, Stefan ; Evans, David ; Paul Wordsworth, B. ; Plant, Darren ; Bowes, John ; Orozco, Gisela ; Morgan, Ann W. ; Wilson, Anthony G. ; Isaacs, John ; Barton, Anne ; Williams, Frances M. ; Livshits, Gregory ; Spector, Tim ; MacGregor, Alexander ; Williams, Frances M. ; Scollen, Serena ; Cao, Dandan ; Memari, Yasin ; Hyde, Craig L. ; Zhang, Baohong ; Sidders, Benjamin ; Ziemek, Daniel ; Shi, Yujian ; Harris, Juliette ; Harrow, Ian ; Dougherty, Brian ; Malarstig, Anders ; McEwen, Robert ; Stephens, Joel L. ; Patel, Ketan ; Shin, So-Youn ; Surdulescu, Gabriela ; He, Wen ; Jin, Xin ; McMahon, Stephen B. ; Soranzo, Nicole ; John, Sally ; Wang, Jun ; Spector, Tim D. ; Baker, Jonathan ; Litherland, Gary J. ; Rowan, Andrew D. ; Kite, Kerry A. ; Bayley, Rachel ; Yang, Peiming ; Smith, Jacqueline P. ; Williams, Julie ; Harper, Lorraine ; Kitas, George D. ; Buckley, Christopher ; Young, Stephen P. ; Fitzpatrick, Martin A. ; Young, Stephen P. ; McGettrick, Helen M. ; Filer, Andrew ; Raza, Karim ; Nash, Gerard ; Buckley, Christopher ; Muthana, Munitta ; Davies, Holly ; Khetan, Sachin ; Adeleke, Gbadebo ; Hawtree, Sarah ; Tazzyman, Simon ; Morrow, Fiona ; Ciani, Barbara ; Wilson, Gerry ; Quirke, Anne-Marie ; Lugli, Elena ; Wegner, Natalia ; Charles, Peter ; Hamilton, Bart ; Chowdhury, Muslima ; Ytterberg, Jimmy ; Potempa, Jan ; Fisher, Benjamin ; Thiele, Geoffrey ; Mikuls, Ted ; Venables, Patrick ; Adebajo, Adewale O. ; Kavanaugh, Arthur ; Mease, Philip ; Gomez-Reino, Juan J. ; Wollenhaupt, Jurgen ; Hu, ChiaChi ; Stevens, Randall ; Sieper, Joachim ; van der Heijde, Desiree ; Dougados, Maxime ; Van den Bosch, Filip ; Goupille, Philippe ; Rathmann, Suchitrita S. ; Pangan, Aileen L. ; van der Heijde, Desiree ; Sieper, Joachim ; Maksymowych, Walter P. ; Brown, Matthew A. ; Rathmann, Suchitrita ; Pangan, Aileen L. ; Sieper, Joachim ; van der Heijde, Desiree ; Elewaut, Dirk ; Pangan, Aileen L. ; Anderson, Jaclyn ; Haroon, Muhammad ; Ramasamy, Pathma ; O'Rourke, Michael ; Murphy, Conor ; Fitzgerald, Oliver ; Jani, Meghna ; Moore, Sarah ; Mirjafari, Hoda ; Macphie, Elizabeth ; Chinoy, Hector ; Rao, Chan ; McLoughlin, Yokemei ; Preeti, Shah

In: Rheumatology, 2013, vol. 52, p. i44-i55

Ajouter à la liste personnelle
    Summary
    Background: This analysis assessed, on a group level, whether there is a long-term advantage for early RA patients treated with adalimumab (ADA) + MTX vs those initially treated with placebo (PBO) + MTX who either responded to therapy or added ADA following inadequate response (IR). Methods: OPTIMA was a 78- week, randomized, controlled trial of ADA + MTX vs PBO + MTX in MTX-naïve early (<1 year) RA patients. Therapy was adjusted at week 26: ADA + MTX-responders (R) who achieved DAS28 (CRP) <3.2 at weeks 22 and 26 (Period 1, P1) were re-randomized to withdraw or continue ADA and PBO + MTX-R continued randomized therapy for 52 weeks (P2); IR-patients received open-label (OL) ADA + MTX during P2. This post hoc analysis evaluated the proportion of patients at week 78 with DAS28 (CRP) <3.2, HAQ-DI <0.5, and/or ΔmTSS ≤0.5 by initial treatment. To account for patients who withdrew ADA during P2, an equivalent proportion of R was imputed from ADA + MTX-R patients. Results: At week 26, significantly more patients had low disease activity, normal function, and/or no radiographic progression with ADA + MTX vs PBO + MTX (Table 1). Differences in clinical and functional outcomes disappeared following additional treatment, when PBO + MTX-IR (n = 348/460) switched to OL ADA + MTX. Addition of OL ADA slowed radiographic progression, but more patients who received ADA + MTX from baseline had no radiographic progression at week 78 than patients who received initial PBO + MTX. Conclusions: Early RA patients treated with PBO + MTX achieved comparable long-term clinical and functional outcomes on a group level as those who began ADA + MTX, but only when therapy was optimized by the addition of ADA in PBO + MTX-IR. Still, ADA + MTX therapy conferred a radiographic benefit although the difference did not appear to translate to an additional functional benefit. Disclosures: P.E., AbbVie, Merck, Pfizer, UCB, Roche, BMS—Provided Expert Advice, Undertaken Trials, AbbVie—AbbVie sponsored the study, contributed to its design, and participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final version. R.F., AbbVie, Pfizer, Merck, Roche, UCB, Celgene, Amgen, AstraZeneca, BMS, Janssen, Lilly, Novartis—Research Grants, Consultation Fees. S.F., AbbVie—Employee, Stocks. A.K., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, UCB—Research Grants, Consultation Fees. H.K., AbbVie—Employee, Stocks. S.R., AbbVie—Employee, Stocks. J.S., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, GlaxoSmithKline, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz, UCB—Research Grants, Consultation Fees. R.V., AbbVie, BMS, GlaxoSmithKline, Human Genome Sciences, Merck, Pfizer, Roche, UCB Pharma—Consultation Fees, Research Support. Table 1.Week 78 clinical, functional, and radiographic outcomes in patients who received continued ADA + MTX vs those who continued PBO + MTX or added open-label ADA following an inadequate response ADA + MTX, n/N (%)a PBO + MTX, n/N (%)b Outcome Week 26 Week 52 Week 78 Week 26 Week 52 Week 78 DAS28 (CRP) <3.2 246/466 (53) 304/465 (65) 303/465 (65) 139/460 (30)*** 284/460 (62) 300/460 (65) HAQ-DI <0.5 211/466 (45) 220/466 (47) 224/466 (48) 150/460 (33)*** 203/460 (44) 208/460 (45) ΔmTSS ≤0.5 402/462 (87) 379/445 (86) 382/443 (86) 330/459 (72)*** 318/440 (72)*** 318/440 (72)*** DAS28 (CRP) <3.2 + ΔmTSS ≤0.5 216/462 (47) 260/443 (59) 266/443 (60) 112/459 (24)*** 196/440 (45) 211/440 (48)*** DAS28 (CRP) <3.2 + HAQ-DI <0.5 + ΔmTSS ≤0.5 146/462 (32) 168/443 (38) 174/443 (39) 82/459 (18)*** 120/440 (27)*** 135/440 (31)** aIncludes patients from the ADA Continuation (n = 105) and OL ADA Carry On (n = 259) arms, as well as the proportional equivalent number of responders from the ADA Withdrawal arm (n = 102). bIncludes patients from the MTX Continuation (n = 112) and Rescue ADA (n = 348) arms. Last observation carried forward: DAS28 (CRP) and HAQ-DI; Multiple imputations: ΔmTSS. ***P < 0.001 and **iP < 0.01, respectively, for differences between initial treatments from chi-square